Related Experiment Video
Updated: Feb 15, 2026
07:42
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
Published on: April 26, 2012
18.6K
Chemotherapy of Oligodendrogliomas
Progress in Neurological Surgery
|February 3, 2018
Summary
Chemotherapy combined with radiation significantly improves survival for oligodendrogliomas with 1p/19q co-deletion. Ongoing studies aim to determine the best chemotherapy regimen for these brain tumors.
Area of Science:
- Neuro-oncology
- Molecular diagnostics
- Cancer therapy
Background:
- Oligodendrogliomas exhibit better prognosis than astrocytic gliomas.
- Treatment goals include survival, neurologic function, and quality of life.
- Traditional treatment involved surgery followed by radiation therapy.
Purpose of the Study:
- To evaluate the impact of combined chemoradiation versus radiation alone for oligodendrogliomas.
- To identify optimal chemotherapy regimens and prognostic markers for oligodendrogliomas.
Main Methods:
- Analysis of prospective randomized trials comparing irradiation with chemoradiation.
- Ongoing clinical trials (e.g., CODEL study) investigating chemotherapy regimens and molecular markers.
Main Results:
- Chemotherapy combined with irradiation significantly prolongs overall survival in 1p/19q co-deleted anaplastic and high-risk low-grade gliomas.
- Median survival in these patients exceeds a decade with combined therapy.
Conclusions:
- Combined chemoradiation is superior to radiation alone for specific oligodendroglioma subtypes.
- Further research is needed to optimize chemotherapy and utilize molecular markers for treatment decisions.
Related Concept Videos
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
802
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
802
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
932
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
932
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
715
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
715
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
652
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
652